These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 33142243)
1. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma. Nguyen MT; Lin CH; Liu SM; Miyashita A; Ihn H; Lin H; Ng CH; Tsai JC; Chen MH; Tsai MS; Lin IY; Liu SC; Li LY; Fukushima S; Lu J; Ma N Neoplasia; 2020 Dec; 22(12):789-799. PubMed ID: 33142243 [TBL] [Abstract][Full Text] [Related]
2. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605 [TBL] [Abstract][Full Text] [Related]
3. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP. Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955 [TBL] [Abstract][Full Text] [Related]
6. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. Kim JH; Ahn JH; Lee M Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651 [TBL] [Abstract][Full Text] [Related]
7. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma. Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038 [TBL] [Abstract][Full Text] [Related]
8. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301 [TBL] [Abstract][Full Text] [Related]
9. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964 [TBL] [Abstract][Full Text] [Related]
10. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators. Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672 [TBL] [Abstract][Full Text] [Related]
11. Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma. Park BS; Jeon H; Kim Y; Kwon H; Choi GE; Chi SG; Park HM; Lee H; Kim T Mol Cancer; 2024 Jul; 23(1):136. PubMed ID: 38965534 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853 [TBL] [Abstract][Full Text] [Related]
13. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Liu SM; Lu J; Lee HC; Chung FH; Ma N Oncotarget; 2014 Oct; 5(19):9444-59. PubMed ID: 25275294 [TBL] [Abstract][Full Text] [Related]
14. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Phadke MS; Sini P; Smalley KS Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592 [TBL] [Abstract][Full Text] [Related]
15. Targeting CDC7 sensitizes resistance melanoma cells to BRAF Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454 [TBL] [Abstract][Full Text] [Related]
16. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor. Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109 [TBL] [Abstract][Full Text] [Related]
17. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. Kozar I; Cesi G; Margue C; Philippidou D; Kreis S Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001 [TBL] [Abstract][Full Text] [Related]
19. MiR-9-5p Inhibits the Proliferation, Migration and Invasion of Choroidal Melanoma by Targeting BRAF. Ying M; Feng H; Zhang X; Liu R; Ning H Technol Cancer Res Treat; 2020; 19():1533033820956987. PubMed ID: 33138697 [TBL] [Abstract][Full Text] [Related]
20. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related] [Next] [New Search]